Figure 8.

Effects of tamoxifen, raloxifene and toremifene on DiI-LDL uptake by lymphocytes from normolipidaemic and FH subjects. Lymphocytes were treated with DiI-LDL and vehicle (control) or 5 μM tamoxifen (TAM), raloxifene (RAL) or toremifene (TOR) for 24 h. (A) NL subjects. (B) HeFH patients. (C) HoFH patients. Data are expressed as % of the inter-assay (i.a.) control. Horizontal lines depict the mean value for each treatment. Statistical analysis was performed by one-way RM anova and post hoc by Student–Newman–Keuls test. *P < 0.05, ***P < 0.001 versus control; ###P < 0.001 versus RAL; §§§P < 0.001 versus TOR.